X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
empagliflozin (568) 568
science & technology (337) 337
life sciences & biomedicine (329) 329
type 2 diabetes (203) 203
diabetes (202) 202
humans (191) 191
canagliflozin (143) 143
diabetes mellitus, type 2 - drug therapy (142) 142
endocrinology & metabolism (140) 140
dapagliflozin (136) 136
glucose (119) 119
diabetes mellitus (115) 115
benzhydryl compounds - therapeutic use (95) 95
glucosides - therapeutic use (95) 95
hypoglycemic agents - therapeutic use (95) 95
heart failure (93) 93
male (90) 90
type 2 diabetes mellitus (89) 89
pharmacology & pharmacy (83) 83
sodium-glucose transporter 2 - antagonists & inhibitors (83) 83
sglt2 inhibitor (78) 78
dextrose (74) 74
female (68) 68
middle aged (67) 67
cardiovascular system & cardiology (63) 63
blood pressure (62) 62
mortality (59) 59
benzhydryl compounds - adverse effects (58) 58
glucosides - adverse effects (58) 58
treatment outcome (57) 57
clinical trials (56) 56
internal medicine (56) 56
hypoglycemic agents - adverse effects (55) 55
sodium (55) 55
aged (54) 54
cardiovascular disease (53) 53
sglt2 inhibitors (53) 53
cardiac & cardiovascular systems (52) 52
analysis (50) 50
metformin (49) 49
risk factors (49) 49
adult (48) 48
medicine & public health (46) 46
cardiovascular diseases (45) 45
hypoglycemic agents (45) 45
animals (44) 44
benzhydryl compounds - administration & dosage (44) 44
benzhydryl compounds - pharmacology (44) 44
glucosides - administration & dosage (44) 44
glucosides - pharmacology (44) 44
insulin (44) 44
review (42) 42
diabetes mellitus, type 2 - blood (41) 41
drug therapy (41) 41
blood glucose - drug effects (40) 40
diabetes mellitus, type 2 - complications (39) 39
care and treatment (38) 38
diabetes therapy (38) 38
hypoglycemic agents - administration & dosage (38) 38
body weight (37) 37
liraglutide (37) 37
cardiology (36) 36
blood pressure - drug effects (35) 35
endocrinology (35) 35
hyperglycemia (35) 35
patients (33) 33
hypertension (32) 32
sglt2 (32) 32
general & internal medicine (31) 31
hypoglycemic agents - pharmacology (31) 31
linagliptin (31) 31
medicine, general & internal (31) 31
double-blind method (30) 30
blood glucose - metabolism (29) 29
hypoglycemia (29) 29
abridged index medicus (28) 28
heart diseases (28) 28
medicine (28) 28
drug therapy, combination (27) 27
glucosides - pharmacokinetics (27) 27
benzhydryl compounds - pharmacokinetics (26) 26
diabetes mellitus, type 2 - metabolism (26) 26
drug dosages (26) 26
hemoglobin (26) 26
kidney diseases (26) 26
diabetes mellitus, type 2 - physiopathology (25) 25
kidneys (25) 25
research (25) 25
rodents (25) 25
insulin resistance (24) 24
sodium-glucose transporter 2 inhibitors - therapeutic use (24) 24
diseases of the circulatory system (23) 23
glycosylated hemoglobin (23) 23
sodium-glucose transporter 2 - metabolism (23) 23
cardiovascular outcomes (22) 22
medical research (22) 22
glucose metabolism (21) 21
peripheral vascular disease (21) 21
glucose transporter (20) 20
inhibitors (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (543) 543
Czech (9) 9
French (7) 7
German (7) 7
Russian (5) 5
Spanish (5) 5
Japanese (3) 3
Portuguese (3) 3
Korean (2) 2
Chinese (1) 1
Polish (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European journal of heart failure, ISSN 1388-9842, 07/2019, Volume 21, Issue 7, pp. 932 - 942
Aims Heart failure (HF) is associated with considerable symptom burden and impairment in physical functioning and quality of life. The sodium–glucose... 
Heart failure | Empagliflozin | Exercise capacity | Sodium–glucose co‐transporter 2 inhibitor | Sodium–glucose co-transporter 2 inhibitor | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Index Medicus | Study Design | Trial Design
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2019, Volume 380, Issue 24, pp. 2295 - 2306
This double-blind, randomized trial compared canagliflozin with placebo in patients with type 2 diabetes and evidence of kidney disease that was treated with... 
KIDNEY-DISEASE | EMPAGLIFLOZIN | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Glomerular Filtration Rate | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diabetic Nephropathies - drug therapy | Male | Canagliflozin - adverse effects | Diabetic Nephropathies - complications | Diabetes Mellitus, Type 2 - blood | Kidney Failure, Chronic - epidemiology | Kidney Failure, Chronic - prevention & control | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Creatinine - blood | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Myocardial infarction | End-stage renal disease | Laboratories | Hemodialysis | Clinical trials | Immunosuppressive agents | Clinical outcomes | Renin | Amputation | Diabetes mellitus (non-insulin dependent) | Heart diseases | Creatinine | Cerebral infarction | Enzymes | Kidneys | Diabetes mellitus | Glomerular filtration rate | Nephropathy | Sodium | Collaboration | Angiotensin | Renal failure | Death | Diabetes | Kidney diseases | Cardiovascular diseases | Kidney transplantation | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 1995 - 2008
In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients... 
NEPRILYSIN INHIBITION | OUTCOMES | COTRANSPORTER 2 INHIBITORS | MECHANISM | EMPAGLIFLOZIN | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Humans | Middle Aged | Ventricular Dysfunction, Left - complications | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Heart Failure - complications | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Kaplan-Meier Estimate | Stroke Volume - drug effects | Combined Modality Therapy | Hospitalization | Heart Failure - drug therapy | Cardiovascular Agents - therapeutic use | Diabetes Mellitus, Type 2 - blood | Ventricular Dysfunction, Left - drug therapy | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Measurement | Heart failure | Dapagliflozin | Patient outcomes | Physiological aspects | Cardiac output | Drug therapy | Testing | Intravenous administration | Renal function | Clinical trials | Hypoglycemia | Evidence-based medicine | Clinical outcomes | Sodium | Hemoglobin | Patient safety | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Ejection fraction | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Clinical therapeutics, ISSN 0149-2918, 08/2015, Volume 37, Issue 8, pp. 1773 - 1788.e1
Journal Article
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, ISSN 1386-1425, 11/2016, Volume 168, pp. 118 - 122
New univariate spectrophotometric method and multivariate chemometric approach were developed and compared for simultaneous determination of empagliflozin and... 
Pharmaceutical preparation | Empagliflozin | Metformin | Chemometry | Partial least squares | Simultaneous equation | Spectroscopy | Technology | Science & Technology | Hypoglycemic agents | Methods | Drugstores | Pharmacy
Journal Article
Endocrinologia y nutricion, ISSN 1575-0922, 12/2016, Volume 63, Issue 10, pp. 519 - 526
Introduction To analyze the efficacy and safety of empagliflozin combined with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.... 
Empagliflozin | SGLT-2 inhibitors | Type 2 diabetes mellitus
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 06/2016, Volume 141, Issue 11, pp. 757 - 760
Zusammenfassung SGLT2-Inhibitoren stellen ein neues Wirkprinzip in der Behandlung des Diabetes mellitus Typ 2 dar. Diese Medikamente bewirken über die... 
Klinischer Fortschritt | empagliflozin | SGLT2 inhibitor | cardovascular risk
Journal Article
Journal Article